{
  "source": "PA-Notification-Cabometyx.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1196-11\nProgram Prior Authorization/Notification\nMedication Cabometyx® (cabozantinib)\nP&T Approval Date 6/2016, 6/2017, 2/2018, 6/2018, 3/2019, 3/2020, 3/2021, 11/2021,\n11/2022, 11/2023, 11/2024\nEffective Date 2/15/2025\n1. Background:\nCabometyx® (cabozantinib) is a kinase inhibitor indicated for the treatment of patients with\nadvanced renal cell carcinoma (RCC), patients with advanced RCC as a first-line treatment\nin combination with Opdivo (nivolumab), patients with hepatocellular carcinoma (HCC)\nwho have been previously treated with Nexavar® (sorafenib tosylate), and in adult and\npediatric patients 12 years of age and older with locally advanced or metastatic\ndifferentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted\ntherapy and who are radioactive iodine-refractory or ineligible.\nThe National Cancer Comprehensive Network (NCCN) recommends Cabometyx for the\ntreatment of non-small cell lung cancer (NSCLC) with RET gene rearrangement and HCC\nas a single agent for progressive disease. Cabometyx is also recommended in NCCN\nguidelines for bone cancer, gastrointestinal stromal tumors (GIST), kidney cancer, soft tissue\nsarcoma, and endometrial carcinoma.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the\nage of 19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium\nreferences. Where such mandates apply, they supersede language in the benefit document or\nin the notification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Cabometyx will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Kidney Cancer\n1. Initial Autho",
    "an 19 years of age\n1. Cabometyx will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Kidney Cancer\n1. Initial Authorization\na. Cabometyx will be approved based on the following criterion:\n© 2024 UnitedHealthcare Services, Inc.\n1\n(1) Diagnosis of one of the following:\n(a) Stage IV or relapsed renal cell carcinoma (RCC)\n(b) Hereditary leiomyomatosis and RCC (HLRCC)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cabometyx will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Cabometyx\ntherapy\nAuthorization will be issued for 12 months.\nC. Non-Small Cell Lung Cancer (NSCLC)\n1. Initial Authorization\na. Cabometyx will be approved based on all of the following criteria:\n(1) Diagnosis of non-small cell lung cancer (NSCLC)\n-AND-\n(2) Positive for RET gene rearrangements\n-AND-\n(3) Disease is one of the following:\n(a) Recurrent\n(b) Advanced\n(c) Metastatic\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cabometyx will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Cabometyx\ntherapy\nAuthorization will be issued for 12 months.\nD. Hepatocellular Carcinoma\n© 2024 UnitedHealthcare Services, Inc.\n2\n1. Initial Authorization\na. Cabometyx will be approved based on all of the following criteria:\n(1) Diagnosis of hepatocellular carcinoma\n-AND-\n(2) Used as subsequent-line systemic therapy\n-AND-\n(3) One of the following:\n(a) Patient has liver-confined, unresectable disease and is not a transplant\ncandidate\n(b) Patient has extrahepatic/metastatic disease and deemed ineligible for\nresection, transplant, or locoregional therapy\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cabometyx will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Cabometyx\ntherapy\nAuthorizati",
    "ssued for 12 months.\n2. Reauthorization\na. Cabometyx will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Cabometyx\ntherapy\nAuthorization will be issued for 12 months.\nE. Bone Cancer\n1. Initial Authorization\na. Cabometyx will be approved based on all of the following criteria:\n(1) One of the following diagnoses:\n(a) Osteosarcoma\n(b) Ewing Sarcoma (including mesenchymal chondrosarcoma)\n-AND-\n(2) Disease is one of the following:\n(a) Relapsed/refractory\n© 2024 UnitedHealthcare Services, Inc.\n3\n(b) Metastatic\n-AND-\n(3) Used as second line therapy\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cabometyx will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Cabometyx\ntherapy\nAuthorization will be issued for 12 months.\nF. Gastrointestinal Stromal Tumors (GIST)\n1. Initial Authorization\na. Cabometyx will be approved based on all the following criteria:\n(1) Diagnosis of GIST\n-AND-\n(2) Patient has one of the following:\n(a) Gross residual disease (R2 resection)\n(b) Unresectable primary disease\n(c) Tumor rupture\n(d) Recurrent/metastatic disease\n-AND-\n(3) Disease has progressed on all of the following:\n(a) Gleevec (imatinib)\n(b) Sutent (sunitinib)\n(c) Stivarga (regorafenib)\n(d) Standard dose Qinlock (ripretinib)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cabometyx will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Cabometyx\ntherapy\n© 2024 UnitedHealthcare Services, Inc.\n4\nAuthorization will be issued for 12 months.\nG. Endometrial Carcinoma\n1. Initial Authorization\na. Cabometyx will be approved based on both of the following criteria:\n(1) Diagnosis of endometrial carcinoma\n-AND-\n(2) Used as second-line or subsequent treatment\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cabometyx will be approved based on the following criteri",
    " endometrial carcinoma\n-AND-\n(2) Used as second-line or subsequent treatment\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cabometyx will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Cabometyx\ntherapy\nAuthorization will be issued for 12 months.\nH. Thyroid Cancer\n1. Initial Authorization\na. Cabometyx will be approved based on all of the following:\n(1) Diagnosis of differentiated thyroid cancer (DTC)\n-AND-\n(2) Disease is locally advanced or metastatic\n-AND-\n(3) Disease has progressed following prior VEGFR-targeted therapy\n-AND-\n(4) Disease is radioactive iodine-refractory or ineligible\nAuthorization will be issued for 12 months.\n2. Reauthorization\n© 2024 UnitedHealthcare Services, Inc.\n5\na. Cabometyx will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Cabometyx\ntherapy\nAuthorization will be issued for 12 months.\nI. Soft Tissue Sarcoma\n1. Initial Authorization\na. Cabometyx will be approved based on both of the following criteria:\n(1) One of the following soft tissue sarcoma subtypes:\n(a) Alveolar soft part sarcoma (ASPS)\n(b) Atypical lipomatous tumor/well-differentiated liposarcoma (ALT/WDLPS)\n(c) Clear cell sarcoma\n(d) Extraskeletal myxoid chondrosarcoma\n-AND-\n(2) Used as subsequent line of therapy for advanced/metastatic disease\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cabometyx will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Cabometyx\ntherapy\nAuthorization will be issued for 12 months.\nJ. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requireme",
    "(NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2024 UnitedHealthcare Services, Inc.\n6\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Cabometyx [prescribing information]. South San Francisco, CA: Exelixis, Inc.; September\n2023.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttp://www.nccn.org/professionals/drug_compendium/content/contents.asp. Accessed\nSeptember 25, 2024.\nProgram Prior Authorization/Notification – Cabometyx (cabozantinib)\nChange Control\n6/2016 New program.\n6/2017 Annual review with no changes to clinical criteria.\n2/2018 Updated background and criteria to include new indication for first line\ntherapy for RCC. Added coverage for NCCN recommended use for\nNSCLC.\n6/2018 Annual review with no changes to clinical criteria.\n3/2019 Updated background and criteria to include new indication for second\nline therapy for HCC and NCCN recommended use for HCC.\n3/2020 Annual review. Updated RCC criteria to only require a diagnosis of\nadvanced renal cell carcinoma to align with label. Added standard\nlanguage for NCCN recommended regimens.\n3/2021 Annual review. Updated background and criteria to include new NCCN\nrecommendations for osteosarcoma, Ewing sarcoma, GIST and kidney\ncancer.\n11/2021 Updated background and criteria to include Endometrial carcinoma and\nnew indication for thyroid cancer. Updated references.\n11/2022 Annua",
    "r osteosarcoma, Ewing sarcoma, GIST and kidney\ncancer.\n11/2021 Updated background and criteria to include Endometrial carcinoma and\nnew indication for thyroid cancer. Updated references.\n11/2022 Annual review. Updated examples of approved therapies for GIST per\nNCCN without change to clinical intent. Added state mandate and\nupdated references.\n11/2023 Annual review. Updated NSCLC, hepatocellular carcinoma, and GIST\ncriteria per NCCN recommendation. Updated background. Updated\nreferences.\n11/2024 Annual review. Consolidated sections and updated coverage criteria for\nkidney cancer and renal cell carcinoma into kidney cancer.\nConsolidated sections and updated coverage criteria for ewing sarcoma\nand osteosarcoma into bone cancer. Added criteria for soft tissue\nsarcoma per NCCN guideline. Updated coverage criteria for\n© 2024 UnitedHealthcare Services, Inc.\n7\nhepatocellular carcinoma and endometrial carcinoma. Updated\nbackground.\n© 2024 UnitedHealthcare Services, Inc.\n8"
  ]
}